The US FDA has turned down Helius Medical Technologies Inc.’s de novo application for the Portable Neuromodulation Stimulator (PoNS) system to treat brain injury after concluding that the company has not provided sufficient information to show therapy with the PoNS device provides benefits beyond what the patient gets from physical therapy.
PoNS is an electrical stimulator placed on the patient’s tongue to stimulate the trigeminal and facial nerves. Research suggests that stimulation of these two cranial nerves, in addition to physical...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?